Patents by Inventor Benjamin R. Lundgren

Benjamin R. Lundgren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10301659
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 28, 2019
    Assignee: National Research Council of Canada
    Inventors: Dennis M. Whitfield, Susan M. Logan, Ian C. Schoenhofen, Christopher N. Boddy, Benjamin R. Lundgren
  • Patent number: 9879051
    Abstract: A synthetic peptide includes an amino acid sequence that: has 70-75%, 75-80%, 80-85%, 85-90%, 90-95% or 95-100% homology with an RpoN box of Region III of an RpoN protein; and binds specifically to a ?24, ?12, or ?24/?12 site(s) of an RpoN promoter. The synthetic peptide is effective for repressing transcription and/or gene expression from a binding site of interest, and the binding site of interest is an RpoN binding site or a cryptic promoter upstream of an RpoN binding site.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 30, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Christopher T. Nomura, Benjamin R. Lundgren
  • Publication number: 20170145459
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Application
    Filed: November 17, 2016
    Publication date: May 25, 2017
    Applicants: National Research Council of Canada, University of Ottawa
    Inventors: Dennis M. WHITFIELD, Susan M. LOGAN, Ian C. SCHOENHOFEN, Christopher N. BODDY, Benjamin R. LUNDGREN
  • Publication number: 20160362452
    Abstract: A synthetic peptide includes an amino acid sequence that: has 70-75%, 75-80%, 80-85%, 85-90%, 90-95% or 95-100% homology with an RpoN box of Region III of an RpoN protein; and binds specifically to a ?24, ?12, or ?24/?12 site(s) of an RpoN promoter. The synthetic peptide is effective for repressing transcription and/or gene expression from a binding site of interest, and the binding site of interest is an RpoN binding site or a cryptic promoter upstream of an RpoN binding site.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 15, 2016
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Christopher T. NOMURA, Benjamin R. LUNDGREN
  • Patent number: 9512455
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: December 6, 2016
    Assignees: National Research Council of Canada, University of Ottawa
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Patent number: 9392790
    Abstract: The present invention relates to, inter alia, a method for repressing transcription and/or gene expression from RpoN binding sites (or promoters) or cryptic promoters upstream of RpoN binding sites. The method comprises providing an agent that specifically and selectively binds to RpoN promoter sequences to inhibit or repress the expression of genes downstream of that promoter; and contacting the RpoN promoter with the agent. Agents for repressing transcription and/or gene expression from RpoN promoters are also provided. The agent can be a composition that binds specifically to the ?24, ?12, or ?24/?12 site(s) for RpoN promoter interference. Synthetic peptides, vectors, and host cells are also provided.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: July 19, 2016
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Christopher T. Nomura, Benjamin R. Lundgren
  • Patent number: 9243240
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: January 26, 2016
    Assignee: Syracuse University
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren
  • Publication number: 20140356912
    Abstract: The present invention relates to the the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Application
    Filed: July 28, 2014
    Publication date: December 4, 2014
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Patent number: 8841099
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: September 23, 2014
    Assignees: National Research Council of Canada, University of Ottawa
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Publication number: 20140273162
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 18, 2014
    Applicant: SYRACUSE UNIVERSITY
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren
  • Publication number: 20140148380
    Abstract: The present invention relates to, inter alia, a method for repressing transcription and/or gene expression from RpoN binding sites (or promoters) or cryptic promoters upstream of RpoN binding sites. The method comprises providing an agent that specifically and selectively binds to RpoN promoter sequences to inhibit or repress the expression of genes downstream of that promoter; and contacting the RpoN promoter with the agent. Agents for repressing transcription and/or gene expression from RpoN promoters are also provided. The agent can be a composition that binds specifically to the ?24, ?12, or ?24/?12 site(s) for RpoN promoter interference. Synthetic peptides, vectors, and host cells are also provided.
    Type: Application
    Filed: May 7, 2012
    Publication date: May 29, 2014
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Christopher T. Nomura, Benjamin R. Lundgren
  • Patent number: 8722365
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: May 13, 2014
    Assignee: Syracuse University
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren
  • Publication number: 20130196381
    Abstract: The present invention relates to the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.
    Type: Application
    Filed: April 20, 2011
    Publication date: August 1, 2013
    Applicants: UNIVERSITY OF OTTAWA, NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
  • Publication number: 20080153133
    Abstract: A metabolically engineered E. coli strain which produces sialic acid and a method of making said strain. In the engineered E. coli cells, the nanT (sialic acid transporter) and nanA (sialic acid adolase) genes are inactivated, and the neuC and neuB genes of sialic acid biosynthesis in Neisseria meningitidis group B are introduced and overexpressed in the nanT? nanA? E. coli cell. In addition, the glucosamine synthase gene, glmS, of E. coli is co-overexpressed with neuB and neuC.
    Type: Application
    Filed: September 26, 2007
    Publication date: June 26, 2008
    Applicant: SYRACUSE UNIVERSITY
    Inventors: Christopher N. Boddy, Benjamin R. Lundgren